MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s43440-021-00341-0

Медицинская библиотека · Pharmacological reports : PR · 2021

Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial.

Toroghi Negar, Abbasian Ladan, Nourian Anahid, Davoudi-Monfared Effat, Khalili Hossein, Hasannezhad Malihe, Ghiasvand Fereshteh, Jafari Sirous, Emadi-Kouchak Hamid, Yekaninejad Mir Saeed

Сравнительное исследованиеСтатьяРандомизированное исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND AND

OBJECTIVES

Corticosteroids are commonly used in the treatment of hospitalized patients with COVID-19. The goals of the present study were to compare the efficacy and safety of different doses of dexamethasone in the treatment of patients with a diagnosis of moderate to severe COVID-19.

METHODS

Hospitalized patients with a diagnosis of moderate to severe COVID-19 were assigned to intravenous low-dose (8 mg once daily), intermediate-dose (8 mg twice daily) or high-dose (8 mg thrice daily) dexamethasone for up to 10 days or until hospital discharge. Clinical response, 60-day survival and adverse effects were the main outcomes of the study.

RESULTS

In the competing risk survival analysis, patients in the low-dose group had a higher clinical response than the high-dose group when considering death as a competing risk (HR = 2.03, 95% CI: 1.23-3.33, p = 0.03). Also, the survival was significantly longer in the low-dose group than the high-dose group (HR = 0.36, 95% CI = 0.15-0.83, p = 0.02). Leukocytosis and hyperglycemia were the most common side effects of dexamethasone. Although the incidence was not significantly different between the groups, some adverse effects were numerically higher in the intermediate-dose and high-dose groups than in the low-dose group.

CONCLUSIONS

Higher doses of dexamethasone not only failed to improve efficacy but also resulted in an increase in the number of adverse events and worsen survival in hospitalized patients with moderate to severe COVID-19 compared to the low-dose dexamethasone. (IRCT20100228003449N31).

Для цитирования: Toroghi Negar, Abbasian Ladan, Nourian Anahid, Davoudi-Monfared Effat, Khalili Hossein, Hasannezhad Malihe, Ghiasvand Fereshteh, Jafari Sirous, Emadi-Kouchak Hamid, Yekaninejad Mir Saeed. Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial.. Pharmacological reports : PR. 2021. DOI: 10.1007/s43440-021-00341-0.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.